Compare

Humanin vs KPV

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Humanin

418 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 52% · Mixed 30% · Unfavorable overall 18%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
169
Focus
99
Sleep quality
180
Lean mass
190
Joint comfort
34

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
85
Nausea
178
Water retention
145
Appetite loss
186
Injection site reaction
33

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.025–3 mg

0.025–0.05 mg
4
0.05–0.1 mg
11
0.1–0.2 mg
14
0.2–0.4 mg
19
0.4–0.6 mg
25
0.6–1 mg
17
1–2 mg
14
2–3 mg
9

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing22stacking20side effects18humanin26

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 32% more positive, and 12% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 24 days · Based on 92 repeat reporters

KPV

865 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 49% · Mixed 42% · Unfavorable overall 9%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Lean mass
-56
Joint comfort
-109
Recovery
-4
Digestive comfort
-125
Skin appearance
-28

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Appetite loss
-140
Injection site reaction
-30
Anxiety
-39
Flushing
-130
Headache
-29

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg

Reports span 0.025–3 mg

0.025–0.05 mg
3
0.05–0.1 mg
14
0.1–0.2 mg
23
0.2–0.4 mg
27
0.4–0.6 mg
18
0.6–1 mg
10
1–2 mg
7
2–3 mg
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing29stacking27side effects15kpv23

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 29% more positive, and 19% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 24 days · Based on 190 repeat reporters

Sources (10)

Published sources linked on the Humanin and KPV wiki pages.

  1. PubMed

    Humanin: a novel mitochondrial-derived peptide that protects against cellular stress

    Hashimoto Y, Niikura T, Ito Y, et al. Proc Natl Acad Sci USA. 2003

    Source
    Wiki study page →
  2. PubMed

    Humanin and the mitochondria in Alzheimer disease

    Mitchell AC, Jiang S, Peterhoff CM, et al. Mol Neurodegener. 2015

    Source
    Wiki study page →
  3. PubMed

    Humanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases

    Hazafa A, Batool A, Ahmad S, et al. Life sciences. 2021

    Source
    Wiki study page →
  4. PubMed

    Role of humanin, a mitochondrial-derived peptide, in cardiovascular disorders

    Rochette L, Meloux A, Zeller M, et al. Archives of cardiovascular diseases. 2020

    Source
    Wiki study page →
  5. PubMed

    KPV tripeptide exerts anti-inflammatory effects in intestinal epithelial cells

    Brzoska T, Luger TA, Maaser C, et al. Dig Dis Sci. 2010

    Source
    Wiki study page →
  6. PubMed

    Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

    Kannengiesser K, Maaser C, Heidemann J, et al. Inflamm Bowel Dis. 2008

    Source
    Wiki study page →
  7. PubMed

    alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells

    Elliott RJ, Szabo M, Wagner MJ, et al. J Invest Dermatol. 2004

    Source
    Wiki study page →
  8. ClinicalTrials.gov

    KPV peptide studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  9. PubMed

    The neuroimmunomodulatory peptide alpha-MSH

    Ichiyama T, Sato S, Okada K, et al. Annals of the New York Academy of Sciences. 2000

    Source
    Wiki study page →